Last updated on April 21, 2014 at 1:20 EDT

Latest Blueprint Medicines Stories

2013-05-21 08:28:36

BALTIMORE, May 21, 2013 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), today announced that it will use its proprietary methodologies and expertise in genomic analysis of defined cancer subtypes to identify novel kinase targets in collaboration with Blueprint Medicines. PGDx is an innovator in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, and Blueprint Medicines is an expert in developing highly selective kinase inhibitors for a...